Here is what Wall Street expected from UnitedHealth today: adjusted EPS of around $4.90. Here is what it got: $6.38. That is not a beat. That is a category reset.
The headline numbers first. Adjusted EPS of $6.38 represented roughly a 30% premium over the $4.91 consensus, while revenue of $112.0 billion was essentially flat sequentially versus Q1. More important than the revenue line is what happened underneath it. UnitedHealth’s medical care ratio fell to 86.7% from 89.4% a year earlier, a result the company tied to product design changes, improved medical management and better aligned pricing. That 270-basis-point compression is the number that actually matters here.
Operating earnings jumped 55% year over year, helped by stronger Medicare Advantage and Optum Health performance. And then came the guidance revision that sent shares toward a 52-week high. Management raised full-year 2026 adjusted EPS guidance to a range of $19.50 to $20.00, up from the prior outlook of greater than $17.75.
What’s interesting is that this is not just a UNH story.
UnitedHealth jumped about 7% in premarket trading on Thursday after the company reported better-than-expected financials and hiked its full-year outlook. Humana, Elevance, and CVS all caught a bid on the read-through. That is the sector trade people are now trying to figure out how to express.
The competitive context matters here. Humana is guiding FY 2026 adjusted EPS to at least $9.00, down from $17.14 in FY 2025, a 47% cliff driven by the Star Ratings headwind. Elevance Health is recovering, but its Q4 2025 benefit expense ratio hit 93.5% and Health Benefits posted an adjusted operating loss in the quarter. UNH is not just winning this quarter. It is lapping a damaged field.
The company narrowed its expected full-year medical care ratio to 88.1% plus or minus 25 basis points, and plans to repurchase at least $5.0 billion in shares during 2026. That buyback authorization has real weight at this size.
The Optum Layer
The part most options traders miss: Optum generated second-quarter revenues of $65.7 billion and earnings from operations of $4.0 billion, representing 160 basis points of margin expansion year over year. The unit supported more than 120 million consumers in the quarter. Optum is now, by itself, one of the largest healthcare companies in the world. It is not priced that way.
UnitedHealth also highlighted artificial intelligence and prior authorization reductions as part of its efficiency push. Those two things together are not a coincidence. This is a business systematically driving down its own cost structure while competitors are still trying to stabilize theirs.
Options Market Snapshot
Humana had 7,021 contracts tied to $355 puts out in August 2026, hitting 46.2% of its own daily share volume.
For traders who believe the managed care recovery is real but narrow, a defined-risk call spread on UNH targeting the $460 to $480 range through August expiry captures the momentum without chasing the gap open. For traders skeptical that UNH can hold its gains while commercial medical cost trends remain elevated, a put spread on HUM into its next earnings date is the cleaner expression. For a neutral posture, an iron condor on ELV into its next report uses the sector volatility without requiring a directional bet.
The Forward Risk Nobody Is Saying Out Loud
Commercial business remains the main drag as medical cost trends are still running above prior expectations, delaying margin recovery. Management has discussed commercial group margins returning to 7% or better over time, but the rebound is framed as multi-year.
That is the part of today’s call worth sitting with. The beat was real. The guidance raise was real. The buyback is real. But the commercial margin recovery timeline just got stretched. That creates a ceiling on how far the rerating can go in the near term, even with today’s momentum.
The company also guided for full-year cash flows from operations of approximately $24.0 billion. At that level, the capital return math is compelling. The valuation debate is not.
The managed care trade is back on the board today. The question is whether today’s gap represents the beginning of a sustained rerating or a short-lived relief rally before commercial cost pressures resurface in the back half of 2026. That answer will take another quarter to know for certain.
